发明名称 OLIGOMERIC COMPOUNDS FOR THE MODULATION OF BCL-2
摘要 <p>The present invention provides improved oligomeric compound, in particular oligonucleotide compounds, and methods for modulating the expression of the Bcl-2 gene in humans. In particular, this invention relates to oligomeric compounds of 10-30 nucleobases in length which comprise a target binding domain that is specifically hybridizable to a region ranging from base position N°1459 (5') to N°1476 (3') of the human Bcl-2 mRNA, said target binding domain having the formula: 5'-[DNA/RNA)0-1-(LNA/LNA*)2-7-(DNA/RNA/LNA*)4-14-(LNA/LNA*)2-7-(DNA/RNA)0-1]-3' and said target binding domain comprising at least two LNA nucleotides or LNA analogue nucleotides linked by a phosphorothioate group (-O-P(O,S)-O). In particular the oligo is predominantly or fully thiolated. The invention also provides the use of such oligomers or conjugates or chimera for the treatment of various diseases associated with the expression of the Bcl-2 gene, such as cancer.</p>
申请公布号 WO2005061710(A1) 申请公布日期 2005.07.07
申请号 WO2004DK00917 申请日期 2004.12.23
申请人 SANTARIS PHARMA A/S;FRIEDEN, MIRIAM;HANSEN, JENS, BO;OERUM, HENRIK;WESTERGAARD, MAJKEN;THRUE, CHARLOTTE, ALBAECK 发明人 FRIEDEN, MIRIAM;HANSEN, JENS, BO;OERUM, HENRIK;WESTERGAARD, MAJKEN;THRUE, CHARLOTTE, ALBAECK
分类号 A61K48/00;C07H21/02;C12N15/113;(IPC1-7):C12N15/11;A61K31/708 主分类号 A61K48/00
代理机构 代理人
主权项
地址